A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Advanced Solid Tumor Clinical Trial

Official title: A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FB849 Administered in Subjects With Advanced Solid Tumors Alone and in Combination With Pembrolizumab

Status Recruiting

Clinical Trial Summary

This is the first-in-human, multicenter, open-label Phase I/II study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of FB849 alone and in combination with pembrolizumab in subjects with advanced solid tumors for whom no standard therapy is available.

Clinical Trial Description

The study will be conducted in 4 parts: Phase I dose-escalation and dose-expansion parts with FB849 monotherapy and Phase II dose-escalation and dose-expansion parts of FB849 in combination with pembrolizumab. The Phase Ia dose-escalation part will use an adaptive study design termed Bayesian optimal interval (BOIN) design to investigate the safety and tolerability of FB849, and determine the maximum tolerated dose (MTD) and preliminary recommended Phase II dose (RP2D) of FB849. A BOIN design is a hybrid of rule-based and model-based design, which has the flexibility of dose escalation and de-escalation and allows more subjects to be enrolled into the doses closest to the target toxicity rate. The Phase Ib dose expansion of FB849 monotherapy part will be initiated once the preliminary RP2D has been determined in the Phase Ia part to provide assessment of safety and anti-tumor activity of FB849 in subjects with advanced solid tumors. It will evaluate FB849 at the preliminary RP2D. Based on data from the Phase Ia part, an additional dose ≥ 1 dose lower than the preliminary RP2D may be evaluated if needed, as determined by the safety monitoring committee (SMC). Subjects will be enrolled using a Simon's two-stage enrollment. If more than 1 dose level cohort is evaluated, subjects will be randomized to a dose level. For each cohort, an interim analysis will be performed prior to opening the second stage of enrollment in each cohort (Simon's two-stage optimal design). Phase IIa enrollment will be initiated after Stage 1 of Phase Ib is completed. The selected RP2D from the prior Phase Ib part and a dose level ≥ 1 dose lower than the RP2D of FB849 will be selected by the SMC and will be evaluated in combination with a standard dose of pembrolizumab. Dose escalation will follow a BOIN design, but with at least 6 subjects at each FB849 dose level. In the Phase IIb part of the study, subjects with Type A cancer, Type B cancer, or Type C cancer will be enrolled in 3 cohorts to evaluate FB849 at the RP2D in combination with a standard dose of pembrolizumab to provide assessments of safety and anti-tumor activity of FB849. Enrollment will follow a Simon's two-stage design enrollment, similar to Phase Ib. Subjects will be monitored for safety, tolerability, and preliminary efficacy throughout the study. Tumor response will be assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 approximately every 6 weeks (± 3 days) in the first 18 weeks, then every 12 weeks (± 7 days) thereafter until disease progression, using computed tomography or magnetic resonance imaging of the chest, abdomen/pelvis, and if clinically indicated additional assessments eg, craniocerebral imaging, bone scan. Treatment with FB849 will continue until the start of a new anti-cancer treatment, disease progression, subject refusal, unacceptable toxicity, death, lost to follow-up, etc, whichever occurs first. Subjects who discontinue treatment due to other reasons than disease progression will continue with tumor assessments as per protocol until disease progression, death, or starting a new anti-cancer treatment. ;

Related Conditions & MeSH terms

• Advanced Solid Tumor

• NCT number: NCT05761223
• Study type: Interventional
• Source: 1ST Biotherapeutics, Inc.
• Contact: 1STBIO Information center
• Phone: +82-31-895-4677
• Email: info@1stbio.com
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 9, 2023
• Completion date: October 2026